Slovenian Pharmaceutical Giant Krka Group Reports Strong Nine-Month Profit Growth
Slovenian pharmaceutical company Krka Group has announced a 13% year-on-year increase in net profit for the first nine months of 2026. Driven by robust sales performance, the company now anticipates exceeding its initial financial targets for the full year, signaling continued growth in its international markets.
FDA Grants Breakthrough Therapy Designation to NVG-291 for Spinal Cord Injury
The U.S. Food and Drug Administration has awarded Breakthrough Therapy designation to NVG-291, a novel therapeutic candidate developed by NervGen Pharma. This designation aims to expedite the development and review of the drug for treating chronic traumatic cervical motor-incomplete spinal cord injury, a condition currently lacking effective pharmacological treatment options.
Spanish Olive Oil Giants Acesur and Dcoop Move to Acquire Deoleo
Spanish olive oil producers Acesur and Dcoop have reportedly secured a deal to acquire Deoleo, the world's largest olive oil bottler. The transaction, valued at approximately 500 million euros, marks a significant consolidation in the global olive oil market, bringing together major industry players to strengthen Spain's position in the sector.
Turkish Authorities Detain 22 in Expired Cancer Medication Fraud Investigation
Turkish law enforcement has detained 22 individuals accused of operating a criminal network involved in the illegal resale of expired cancer medications. The operation, which spanned multiple provinces, targeted drugs that had passed their expiration dates, posing significant health risks to patients. Authorities continue to investigate the scope of the distribution network.
Swiss Market Index Hits Record High Amid Strong Performance from Heavyweights
The Swiss stock market, represented by the Swiss Market Index (SMI), has reached a new all-time high. The record-breaking performance was driven by significant gains among major blue-chip companies, including pharmaceutical giants Novartis and Roche, as well as food and beverage leader Nestlé, reflecting positive investor sentiment in the Swiss economy.
Australian mRNA Therapeutics Market Forecast to Reach USD 1.78 Billion by 2035
The Australian mRNA therapeutics sector is poised for substantial expansion, with market projections estimating a valuation of USD 1.78 billion by 2035. This growth is underpinned by strategic government initiatives and increased private sector investment aimed at establishing Australia as a global hub for mRNA research, development, and manufacturing.
Rhythm Pharmaceuticals Launches IMCIVREE in Japan for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals has officially launched IMCIVREE (setmelanotide) in Japan. It is the first therapy approved in the country for the treatment of obesity caused by acquired hypothalamic injury, offering a new medical option for patients suffering from this rare and complex condition.
Cuba Implements New Regulations for Private Pharmacy Sector
The Cuban government has introduced new regulatory frameworks for private pharmacies as part of ongoing economic reforms. These measures aim to address chronic medication shortages and improve the distribution of essential pharmaceutical products across the country amid a challenging economic climate.
Grassroots Initiatives Expand Access to Essential Medicines in Havana
Amid persistent economic challenges and pharmaceutical shortages in Cuba, community-led initiatives and local projects in Havana are stepping up to provide essential medicines to citizens, offering a vital lifeline for those struggling to access standard healthcare supplies.
Supreme Court of India Directs Government to Form Panel on Pharma Marketing Practices
The Supreme Court of India has ordered the Union government to constitute an expert committee to address unethical marketing practices in the pharmaceutical industry. The directive aims to ensure transparency and accountability, following concerns regarding the influence of pharmaceutical companies on medical professionals and patient welfare.
Italy's Data Protection Authority Fines IQVIA 7 Million Euros Over Health Data Handling
Italy's Garante per la protezione dei dati personali has fined IQVIA Solutions Italy 7 million euros. The penalty follows an investigation revealing that the company failed to properly anonymize health data belonging to approximately one million patients, violating European data protection regulations.
Saudi Arabia Intensifies Regulatory Crackdown on Unauthorized Peptide Sales
Saudi authorities have launched a nationwide campaign to curb the illegal online sale of peptides. The Saudi Food and Drug Authority (SFDA) is targeting unauthorized platforms and distributors to protect public health, warning that these substances often lack safety approvals and pose significant risks to consumers.
Paramount Reaches Settlement with States Over Proposed Merger
Paramount has secured a settlement with California and other U.S. states regarding its proposed $81 billion merger with Warner Bros. Discovery. This agreement resolves regulatory concerns and marks a significant step forward in the consolidation process for the media giants, aiming to reshape the competitive landscape of the entertainment industry.
All 50 States Join Federal Medicaid Drug Pricing Initiative
In a significant healthcare policy development, the Trump administration announced that all 50 U.S. states have agreed to participate in a new Medicaid drug pricing model. Designed to curb rising prescription costs, the initiative aims to increase transparency and leverage collective purchasing power to secure better pricing for state Medicaid programs across the country.
Pharmac Proposes Expanded Access to Gout Medication Febuxostat in New Zealand
Associate Health Minister David Seymour has announced a Pharmac proposal to widen funded access to the gout medication febuxostat. The move aims to improve treatment options for thousands of New Zealanders suffering from the condition, with the proposal currently open for public consultation to gather feedback from patients, clinicians, and the wider health sector.
Walmart Reaches $3.1 Billion Settlement Over Opioid Prescription Claims
Walmart has finalized a $3.1 billion settlement with the U.S. Department of Justice and various state governments. The agreement resolves long-standing allegations that the retail giant failed to properly oversee opioid prescriptions, contributing to the national opioid crisis. The settlement includes requirements for enhanced compliance and monitoring protocols.
Shionogi and SUSMED Terminate Partnership for Insomnia Digital Therapeutic
Shionogi & Co. and SUSMED Co. have mutually agreed to terminate their commercialization agreement for a digital therapeutic application designed to treat insomnia in Japan. The decision ends a strategic partnership focused on bringing digital health solutions to the Japanese market, with both companies citing a strategic realignment regarding the product's future development.
South African Manufacturers Strengthen Role in Continental Healthcare Supply Chains
South African pharmaceutical and medical device manufacturers are scaling operations to bolster regional healthcare supply chains. Leveraging the African Continental Free Trade Area (AfCFTA), these companies aim to reduce reliance on imports and enhance medicine security across the continent through increased intra-African trade and manufacturing capacity.
Rybelsus Launched in UK Pharmacies for Private Weight Management
A daily oral medication, Rybelsus, containing the active ingredient semaglutide, is now available in UK pharmacies via private prescription. While primarily indicated for type 2 diabetes, the drug is being prescribed off-label for weight management, offering an alternative to injectable treatments for eligible patients seeking to manage their health.
US Judge Rules Against Pentagon in WuXi AppTec Military Designation Case
A US federal judge has ruled against the Department of Defense, blocking the Pentagon from designating WuXi AppTec as a 'Chinese military company.' The court found that the government failed to provide sufficient evidence to support the classification, marking a significant legal setback for the Pentagon's efforts to restrict the Chinese pharmaceutical giant's operations in the United States.